Every 10-Q that Maravai LifeSciences Holdings, Inc. (MRVI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRVI filings page.
Maravai LifeSciences reported improved results for the quarter and six months ended June 30, 2026. Revenue reached $51,442 thousand in Q2 and $117,279 thousand year‑to‑date, led by TriLink growth. Gross margin rose to 40.1% in Q2 and 46.3% for the first half.
The company still recorded a net loss attributable to Maravai of $12,416 thousand in Q2 and $16,149 thousand year‑to‑date, but Adjusted EBITDA turned positive at $8,674 thousand for Q2 and $29,001 thousand for the first half. Operating cash flow improved to an inflow of $12,657 thousand, while cash and restricted cash declined to $70,581 thousand after refinancing into a new $150.0 million term loan maturing in 2032. Management does not expect further high‑volume CleanCap® revenue from commercial COVID‑19 vaccine programs in 2026.
Maravai LifeSciences reported stronger results for the three months ended March 31, 2026. Revenue rose to $65.8 million from $46.9 million, driven mainly by its TriLink segment, which increased to $47.5 million, while Cygnus revenue was stable at $18.4 million.
Gross margin improved sharply to 51.2% from 16.5% as cost of revenue fell and product mix shifted, helped by $14.3 million of high-volume CleanCap® COVID-19 vaccine orders. Net loss narrowed to $6.4 million from $52.9 million, and Adjusted EBITDA turned to a $20.3 million profit from a $10.5 million loss.
Operating expenses declined significantly due to the 2025 Corporate Realignment Plan, which reduced selling, general and administrative and research and development spending but added $2.9 million of restructuring costs. The company used cash to voluntarily prepay $50.0 million of its Term Loan, lowering long‑term debt to $242.9 million while ending the quarter with $165.9 million in cash and cash equivalents.
Maravai LifeSciences (MRVI) reported a weaker Q3 2025 as revenue fell to $41.6 million from $69.0 million a year ago, driven by lower Nucleic Acid Production demand. The quarter posted a net loss attributable to MRVI of $25.6 million (basic and diluted loss per share $0.18) with a loss from operations of $41.0 million.
Year to date, revenue was $135.9 million versus $202.6 million in 2024, and the operating loss reached $156.5 million. Results include a $42.9 million goodwill impairment taken earlier in 2025 and a Q3 $7.4 million restructuring charge tied to a plan that reduces the workforce by about 25% and narrows facilities.
By segment in Q3, Nucleic Acid Production delivered $25.4 million and Biologics Safety Testing $16.3 million. Cash and cash equivalents were $243.6 million at September 30, down from $322.4 million at year end, as operating activities used $34.8 million year‑to‑date. The company closed two tuck‑in deals in 2025: Molecular Assemblies assets for $11.2 million and Officinae Bio for $15.1 million, adding developed technologies to support RNA/DNA workflows.
Maravai LifeSciences reported a weaker first half of 2025 with total revenue of $94.2 million versus $133.6 million in the prior-year six-month period, and second-quarter revenue of $47.4 million versus $69.4 million a year earlier. The company recorded a consolidated net loss of $122.7 million for the six months, of which $69.5 million was attributable to Maravai and $53.2 million to non-controlling interests. Operating results were materially affected by $42.9 million of goodwill impairment recognized in the six months.
Balance sheet highlights show $269.9 million of cash and cash equivalents and $896.97 million of total assets at June 30, 2025, down from $322.4 million cash and $1.008 billion total assets at year-end. The company completed two small acquisitions—Molecular Assemblies (asset purchase, ~$11.2M) and Officinae Bio (~$15.1M)—and recorded related intangible assets and goodwill. A government cooperative agreement provided a $38.8 million award for facility construction, and contingent consideration of $4.94 million was recorded as of June 30, 2025.